If the initial promise of these experiments is confirmed in the clinical setting, we would suggest the following protocol: First, screen the sera of patients with breast cancer to identify patients making antibodies to TrkB, (or for that matter, to any other growth factor receptor). Here, NTRK2 is linked to breast carcinoma.